147 related articles for article (PubMed ID: 36520365)
1. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
Yang Y; Wang S; Cai J; Liang J; Zhang Y; Xie Y; Luo F; Tang J; Gao Y; Shen S; Feng H; Li Y
Cell Oncol (Dordr); 2023 Feb; 46(1):133-143. PubMed ID: 36520365
[TBL] [Abstract][Full Text] [Related]
2. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
[TBL] [Abstract][Full Text] [Related]
3. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
4. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
[TBL] [Abstract][Full Text] [Related]
5. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
6. Rho-associated kinase is a therapeutic target in neuroblastoma.
Dyberg C; Fransson S; Andonova T; Sveinbjörnsson B; Lännerholm-Palm J; Olsen TK; Forsberg D; Herlenius E; Martinsson T; Brodin B; Kogner P; Johnsen JI; Wickström M
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6603-E6612. PubMed ID: 28739902
[TBL] [Abstract][Full Text] [Related]
7. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
[TBL] [Abstract][Full Text] [Related]
8. Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity.
Alptekin A; Ye B; Yu Y; Poole CJ; van Riggelen J; Zha Y; Ding HF
Oncogene; 2019 Dec; 38(50):7504-7520. PubMed ID: 31444411
[TBL] [Abstract][Full Text] [Related]
9. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
[TBL] [Abstract][Full Text] [Related]
11. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.
Hu X; Liu R; Hou J; Peng W; Wan S; Xu M; Li Y; Zhang G; Zhai X; Liang P; Cui H
Oncogene; 2022 Sep; 41(37):4295-4306. PubMed ID: 35978151
[TBL] [Abstract][Full Text] [Related]
12. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
13.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
14. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
15. L1-CAM knock-down radiosensitizes neuroblastoma IMR-32 cells by simultaneously decreasing MycN, but increasing PTEN protein expression.
Rached J; Nasr Z; Abdallah J; Abou-Antoun T
Int J Oncol; 2016 Oct; 49(4):1722-30. PubMed ID: 27432152
[TBL] [Abstract][Full Text] [Related]
16. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
17. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
18. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
19. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
